BioSpace News Archive

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced that Philippe Tinmouth has been appointed as Chief Business and Strategy Officer.

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Mr. James Kinley as the Company’s Chief Financial Officer (“CFO”), effective December 1, 2021.

First Wave BioPharma, Inc.,, a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that an independent data monitoring committee has recommended that enrollment continue in Part 2 of the ongoing RESERVOIR Phase 2 trial evaluating FW-COV as a treatment for COVID-19-related gastrointestinal infections.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Japan Patent Office has issued Japanese Patent No. 6967532 for KETABET™, a combination formulation of FDA-approved ketamine and betaine anhydrous, which has shown in research to enhance the antidepressant effect while having the potential to reduce the known negative side effects of ketamine significantly.

Treadwell Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to evaluate CFI-402257.

AMF Medical is proud to announce that its Sigi™ Insulin Management System, for diabetes mellitus treatment, has met the criteria and has been granted Breakthrough Device Designation by the US Food and Drug Administration.

Ardelyx, Inc. today announced plans to launch IBSRELA, the company’s approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022.

New approaches for ocular drug delivery have expanded the horizon for ophthalmic drugmakers.

Fact.MR – A Market Research and Competitive Intelligence Provider: Microplate Absorbance Reader Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per an exhaustive survey published by Fact.MR, the global medical device coating market is expected to total US$ 1.2 Bn in 2021.